<DOC>
	<DOC>NCT02961218</DOC>
	<brief_summary>To determine the effect of canakinumab versus placebo on daily pain experienced by sickle cell anemia patients (Reduction of average daily pain VAS over the period of Week 8 to 12 as compared to baseline levels).</brief_summary>
	<brief_title>Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia, Sickle Cell</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Male and female subjects ages 1220 years of age (both inclusive) diagnosed with sickle cell anemia (HbSS) or sickle beta0 thalassemia (documented by family studies, or analysis of either hemoglobin or DNA). Patient's written informed consent from those ≥18 years of age must be obtained before any assessment is performed. Parent or legal guardian's written informed consent and child's assent, if appropriate, are required before any assessment is performed for patients &lt; 18 years of age. Detectable baseline of background or episodic pain measured by daily ediary over 1 to 2 weeks during screening period as defined below: Average daily pain score ≥ 1 cm without analgesic use over a period of at least 7 days and/or, At least one episode of pain requiring analgesic use during a period of up to 14 days. History of ≥3 vasoocclusive pain episodes in the past year, as defined as pain with no other, nonsickle cell identifiable cause that requires analgesia and interferes with activities of daily living for more than 2h. History of known hypersensitivity to canakinumab. Ongoing or treatment with the past 2 years with red blood cell transfusion therapy, or have evidence of iron overload requiring chelation therapy. Transcranial Doppler ultrasound in the past year demonstrating velocity in middle or anterior cerebral or internal carotid artery y ≥200 cm/sec. Administration of any other blood products within 3 weeks of screening visit. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Sickle cell disease</keyword>
	<keyword>hemoglobinopathy</keyword>
	<keyword>pediatric</keyword>
</DOC>